Piperazine derivatives as HIV protease inhibitors

US9840478B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Peter D. Williams · Harleysville, US
• John A. McCauley · Maple Glen, US
• David Jonathan Bennett · Watertown, US
• Christopher James Bungard · Lansdale, US
• Lehua Chang · Ramsey, US
• Michael P. Dwyer · Scotch Plains, US
• M. Katharine Holloway · Lansdale, US
• Kartik M. Keertikar · Plainsboro, US
• H. Marie Loughran · Perkasie, US
• Jessie J. Manikowski · Worcester, US
• Gregori J. Morriello · Dover, US
• Dong-Ming Shen · Edison, US
• Edward C. Sherer · Manville, US
• Jurgen Schultz · Scotland, GB
• Sherman T. Waddell · Westfield, US
• Catherine M. Wiscount · Allentown, US
• Nicolas Zorn · Durmenach, FR
• Xin-Jie Chu · Livingston, US
• Satyanarayana Tummanapalli · Singapore, SG
• Vijayasaradhi Sivalenka · Singapore, SG
• Bin Hu · Mesa, US
• Tao Ji · Amherst, US
• Bin Zhong · Shanghai, CN

Key dates

• Filing date: Jul 29, 2014
• Grant date: Dec 12, 2017
• Expiry date: Jul 29, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.